Clinical factors affecting prognosis of limb osteosarcoma in China: a multicenter retrospective analysis. Issue 8 (August 2020)

• Record Type: Journal Article
• Authors: Han, Jia; Yu, Yiyang; Wu, Sujia; Wang, Zhen; Zhang, Weibin; Zhao, Ming; Yao, Yang; Hu, Yongcheng; Wang, Wenjian; Liu, Xiaozhou; Yu, Wenxi; Cheng, Jie; Yu, Lili; Bao, Qiyuan; Zhang, Guochuan; Yu, Xiuchun; Song, Ruoxian
• Is Part Of: Journal of international medical research. Volume 48:Issue 8(2020)
• Publication Date: 2020-08
• Subjects: Osteosarcoma -- multicenter analysis -- prognosis -- chemotherapy -- recurrence -- metastasis; Medicine -- Periodicals; Pharmacology -- Periodicals; 610.5
• DOI: 10.1177/0300060520920053
• Languages: English
• ISSNs: 0300-0605

Abstract

Objective: This study was performed to explore the relationship between various clinical factors and the prognosis of limb osteosarcoma. Methods: We retrospectively analyzed the clinical data of 336 patients with limb osteosarcoma treated from June 2000 to August 2016 at 7 Chinese cancer centers. Data on the patients' clinical condition, treatment method, complications, recurrences, metastasis, and prognosis were collected and analyzed. Kaplan–Meier analysis and Cox regression models were used to analyze the data. Results: The patients comprised 204 males and 132 females ranging in age from 6 to 74 years (average, 21.1 years). The overall 3- and 5-year survival rates were 65.0% and 55.0%, respectively. The 5-year overall survival rate was 64.0% with standard chemotherapy and 45.6% with non-standard chemotherapy. Cox regression analysis demonstrated that standard chemotherapy, surgery, recurrence, and metastasis were independent factors associated with the prognosis of limb osteosarcoma. Conclusion: The survival of patients with limb osteosarcoma can be significantly improved by combining standard chemotherapy and surgery. The overall survival rate can also be improved by adding methotrexate to doxorubicin–cisplatin–ifosfamide triple chemotherapy.